CADRENAL THERAPEUTICS, INC.

Highlights Cadrenal Therapeutics, Inc.

Equities

CVKD

US1276361086

Market Closed - Nasdaq Other stock markets 16:30:00 2024-06-14 EDT			5-day change	1st Jan Change
0.4801 ^USD	+8.42%		+2.02%	-35.11%

05-09	Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-09	Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts	04-09	CI
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Cadrenal Therapeutics Highlights Additional Need for A New Vitamin K Antagonist Following Updates from the Recent European Society of Cardiology Congress	23-09-05	CI
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Cadrenal Therapeutics, Inc. Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases	23-08-01	CI
Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Eleven Months Ended December 31, 2022	23-03-30	CI
Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023	23-02-08	PR
Cadrenal Shares Rise 7% After Tecarfarin's FDA Fast-Track Designation	23-01-23	DJ
Cadrenal Therapeutics Gets Fast Track Label for Tecarfarin	23-01-23	MT
Cadrenal Therapeutics Receives FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation	23-01-23	CI
Cadrenal Therapeutics, Inc. has completed an IPO in the amount of $7 million.	23-01-20	CI
Cadrenal Therapeutics, Inc. has filed an IPO in the amount of $10 million.	22-09-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer